NRX Pharmaceuticals Inc. buy me8
Start price
29.12.21
/
0%
€4.60
Target price
29.12.22
-
Performance (%)
-3.04%
End price
08.01.22
€4.46
Summary
This prediction ended on 08.01.22 with a price of €4.46. With a performance of -3.04%, the BUY prediction for NRX Pharmaceuticals Inc. by me8 closed slightly in the red. This prediction was marked as speculative and is excluded from me8's performance statistics.Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
NRX Pharmaceuticals Inc. | - | - | - |
iShares Core DAX® | 1.937% | 1.473% | 18.596% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% |
According to me8 what are the pros and cons of NRX Pharmaceuticals Inc. for the foreseeable future?
Pros
Capable Management
Could be worthwhile Investment >10% per year
Innovative
Cons
Few uniques
Comments by me8 for this prediction
In the thread NRX Pharmaceuticals Inc. diskutieren
Buy NRX Pharmaceuticals Inc.
In the thread Trading NRX Pharmaceuticals Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by me8 for NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.25
29.11.21
29.11.21
€14.00
29.11.22
29.11.22
-34.55%
11.12.21
11.12.21
Capable Management
Could be worthwhile Investment >10% per year
Innovative
Few uniques
NRX Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.95
23.08.21
23.08.21
€17.00
23.08.22
23.08.22
24.62%
04.09.21
04.09.21
Capable Management
Could be worthwhile Investment >10% per year
Innovative
Few uniques
NRX Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€13.50
09.08.21
09.08.21
€18.00
09.08.22
09.08.22
-25.19%
21.08.21
21.08.21
Capable Management
Could be worthwhile Investment >10% per year
Innovative
Few uniques
NRX Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€11.05
12.07.21
12.07.21
€15.00
12.07.22
12.07.22
86.43%
23.07.21
23.07.21
Capable Management
Could be worthwhile Investment >10% per year
Innovative
Few uniques